The Latest Breaking News from Sanofi

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

The Paris Olympics have been a showcase not only for athletic prowess but also for therapies such as ice baths and osteopathy which have little scientifically proven medical value, according to experts.

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

It’s rather exceptional that a G7 Olympic host gets the support of so many of its largest companies.

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Allergies happen when your immune system overreacts to a normally harmless substance like dust or pollen. Hay fever, hives and anaphylaxis are all types of allergic reactions.

Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.

Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.